StockNews.com Upgrades Kamada (NASDAQ:KMDA) to Strong-Buy

Kamada (NASDAQ:KMDA) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Thursday.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Kamada in a research note on Thursday, March 6th.

Kamada Stock Down 0.7 %

Shares of NASDAQ:KMDA opened at $7.18 on Thursday. The company’s fifty day moving average is $7.22 and its two-hundred day moving average is $6.20. Kamada has a 12-month low of $4.74 and a 12-month high of $9.15. The company has a market cap of $412.71 million, a P/E ratio of 25.64, a price-to-earnings-growth ratio of 0.97 and a beta of 0.97.

Hedge Funds Weigh In On Kamada

A number of hedge funds have recently modified their holdings of the stock. NewEdge Advisors LLC increased its stake in shares of Kamada by 54.2% in the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock worth $143,000 after acquiring an additional 8,260 shares during the last quarter. Aristides Capital LLC increased its position in Kamada by 12.1% during the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock worth $387,000 after buying an additional 6,850 shares during the last quarter. Geode Capital Management LLC increased its position in Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock worth $178,000 after buying an additional 1,549 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in Kamada during the fourth quarter worth $67,000. Finally, Public Employees Retirement System of Ohio acquired a new position in Kamada during the third quarter worth $77,000. 20.38% of the stock is owned by institutional investors and hedge funds.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.